NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits may be filed on behalf of shareholders of Ampio Pharmaceuticals, Inc. AMPELottery.com, Inc. LTRY LTRYW))), NIO, Inc. NEVERand Bed Bath & Beyond, Inc. BBBY. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Ampio Pharmaceuticals, Inc. AMPE

Class Period: December 29, 2020 – August 3, 2022

Lead Plaintiff Deadline: October 17, 2022

The lawsuit stems from the Company’s misrepresentations regarding the ability of Ampion, its lead product, to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (“OAC”).

From 2010 to around March 2022, Ampio conducted numerous clinical studies and analyzes to determine the effectiveness of Ampion. Although confidentially advertised on numerous occasions that Ampion demonstrated a statistically significant reduction in pain associated with symptomatic moderately severe OAC, the company failed to bring Ampion to market.

On April 20, 2022, Ampio announced that the U.S. Food and Drug Administration (“FDA”) has responded negatively to its Type-C meeting request for the Company’s AP-013 clinical study and that the FDA has determined that the company should have obtained FDA approval for changes to data analysis prior to analyzing and unblinding the data.

As a result of this news, the company’s share price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.

Then, on May 16, 2022, Ampio announced that it had formed a special committee to conduct an internal investigation focused on Ampio’s AP-013 clinical trial and the unauthorized making available of its anti-inflammatory drug, Ampion, for use by people who are not participate in clinical trials.

As a result of this news, the company’s share price fell $0.04, or 10%, to close at $0.18…